Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novartis And Cell Therapeutics Suspend Xyotax Development

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

CTI and Novartis are temporarily suspending the PIONEER lung cancer trial to evaluate mortality signals and amend the study protocol.

You may also be interested in...



Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Novartis’ oncology chief discusses in-licensing candidates, as well as how biologics fit into the firm’s oncology pipeline.

Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Novartis’ oncology chief discusses in-licensing candidates, as well as how biologics fit into the firm’s oncology pipeline.

Cell Therapeutics Files For SPA On New Xyotax Study

Study will narrow enrollment for Novartis-partnered compound to women with normal estrogen levels, CEO tells "The Pink Sheet" DAILY.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS063472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By